The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

For symptomatic ILD/pneumonitis (Grade 2 or greater ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The green light from the European Commission means that Enhertu (trastuzumab deruxtecan ... risk of interstitial lung disease (ILD) and pneumonitis with AZ and Daiichi Sankyo's drug.

(A, B) T-DXd, Trastuzumab deruxtecan; HR, Hormone receptor ... and other cancers revealed an overall incidence of adjudicated ILD/pneumonitis to be 15.4%, with most cases being categorized as ...

For symptomatic ILD/pneumonitis (Grade 2 or greater), promptly initiate ... to address the biologically diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ...

For symptomatic ILD/pneumonitis (Grade 2 or greater ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except in ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Pneumonia is a lung infection caused by bacteria, viruses, fungi, or tuberculosis. Symptoms include fever, cough, chest pain, and shortness of breath. Early diagnosis and treatment are crucial to ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...